Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Thrombin
Therapeutic Area : Hematology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 05, 2018
Lead Product(s) : Thrombin
Therapeutic Area : Hematology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Thrombin
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Sponsor : The Ottawa Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With (HHT)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 22, 2015
Lead Product(s) : Thrombin
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Sponsor : The Ottawa Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Thrombin
Therapeutic Area : Hematology
Study Phase : Phase IV
Sponsor : Johnson & Johnson
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 24, 2014
Lead Product(s) : Thrombin
Therapeutic Area : Hematology
Highest Development Status : Phase IV
Sponsor : Johnson & Johnson
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Thrombin
Therapeutic Area : Hematology
Study Phase : Phase IV
Sponsor : Johnson & Johnson
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase IV Bioseal Study in Brain Tumor Surgery
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 14, 2014
Lead Product(s) : Thrombin
Therapeutic Area : Hematology
Highest Development Status : Phase IV
Sponsor : Johnson & Johnson
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Thrombin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Baxter Healthcare Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Prevention of Pelvic Lymphocele by Floseal During Pelvic Lymphadenectomy for Gynecologic Cancer
Details : Undisclosed
Product Name : Floseal
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 01, 2013
Lead Product(s) : Thrombin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Baxter Healthcare Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Thrombin
Therapeutic Area : Hematology
Study Phase : Phase IV
Sponsor : Baxter Healthcare Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Floseal
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 03, 2013
Lead Product(s) : Thrombin
Therapeutic Area : Hematology
Highest Development Status : Phase IV
Sponsor : Baxter Healthcare Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable